| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SIGLEC9/CD329 |
| Uniprot No | Q9Y336 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18-348aa |
| 氨基酸序列 | ADPQTSKLLTMQSSVTVQEGLCVHVPCSFSYPSHGWIYPGPVVHGYWFRE GANTDQDAPVATNNPARAVWEETRDRFHLLGDPHTKNCTLSIRDARRSDA GRYFFRMEKGSIKWNYKHHRLSVNVTALTHRPNILIPGTLESGCPQNLTC SVPWACEQGTPPMISWIGTSVSPLDPSTTRSSVLTLIPQPQDHGTSLTCQ VTFPGASVTTNKTVHLNVSYPPQNLTMTVFQGDGTVSTVLGNGSSLSLPE GQSLRLVCAVDAVDSNPPARLSLSWRGLTLCPSQPSNPGVLELPWVHLRD AAEFTCRAQNPLGSQQVYLNVSLQSKATSGVTQGLEPKSCDKTHTCPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGKHHHHHH |
| 预测分子量 | 66 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Siglec-9. a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes"** by Angata T, et al.
摘要：该文献报道了SIGLEC9的分子克隆、重组蛋白表达及其与唾液酸配体的结合特性，发现其在髓系细胞(如单核细胞和中性粒细胞)中高表达，并参与免疫调节功能。
2. **"Recombinant Siglec-9 mediates apoptosis in human neutrophils through interaction with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)"** by Alphey MS, et al.
摘要：研究利用重组SIGLEC9蛋白探究其与中性粒细胞的相互作用，发现其通过结合TRAIL受体诱导细胞凋亡，为炎症调控提供了新机制。
3. **"Targeting Siglec-9 in cancer: Recombinant protein and antibody-based strategies to modulate immune checkpoint function"** by Hudak JE, et al.
摘要：该研究开发了重组SIGLEC9蛋白及其抗体，验证其通过阻断唾液酸介导的免疫抑制信号增强抗肿瘤T细胞活性，提示其作为癌症免疫治疗靶点的潜力。
4. **"Structural basis for recognition of sialylated glycans by Siglec-9 in bacterial immune evasion"** by Chang L, et al.
摘要：通过X射线晶体学解析重组SIGLEC9蛋白与病原体表面唾液酸化聚糖的复合物结构，揭示其在宿主-微生物互作中的关键作用及潜在治疗应用。
**SIGLEC-9/CD329 Recombinant Protein: Background**
SIGLEC-9 (sialic acid-binding immunoglobulin-type lectin-9), also known as CD329. is a transmembrane protein belonging to the SIGLEC family of immune regulatory receptors. These receptors are characterized by their ability to bind sialic acid-containing glycans on cell surfaces, modulating immune responses through inhibitory signaling. SIGLEC-9 is predominantly expressed on myeloid cells, including neutrophils, monocytes, and macrophages, and plays a critical role in maintaining immune homeostasis by dampening excessive inflammation.
Structurally, SIGLEC-9 contains an N-terminal V-set immunoglobulin domain responsible for sialic acid recognition, followed by multiple C2-set domains, a transmembrane region, and a cytoplasmic tail with immunoreceptor tyrosine-based inhibitory motifs (ITIMs). These ITIMs recruit phosphatases like SHP-1/SHP-2 to suppress activation signals, thereby regulating phagocytosis, cytokine release, and cell survival.
Recombinant SIGLEC-9/CD329 protein is engineered for in vitro studies, often produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper glycosylation and functionality. It is purified via affinity chromatography, typically as a soluble extracellular domain fused with Fc tags or labeled for detection. This recombinant tool enables research into SIGLEC-9’s ligand interactions, its role in immune tolerance, and its involvement in diseases like cancer, sepsis, and autoimmune disorders. Notably, tumor cells exploit SIGLEC-9’s inhibitory signaling to evade immune surveillance, making it a potential target for checkpoint blockade therapies. Studies also explore its dual role in infections, where it may either suppress harmful inflammation or facilitate pathogen recognition.
Overall, recombinant SIGLEC-9/CD329 is vital for dissecting immune regulation mechanisms and developing therapeutic strategies targeting siglec-mediated pathways.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
